Ocular Therapeutix, Inc
OCUL Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$6.50
KIRA · Stoqly’s AI analyst, in plain words
- Ocular Therapeutix, Inc had $52.0M of revenue in fiscal 2025, down 18.5% on the year before. Over five years, revenue changed +24.4% a year on average.
- Its operating margin was −519.8%, down 250.2 pts: of every 100 in sales, about −520 is left after running the business.
- Ocular Therapeutix, Inc lost $266M in fiscal 2025.
- Free cash flow was −$217M in fiscal 2025, −417.5% of revenue.
Market cap
$1.5B
P/E
—
Revenue
$52.0M
Net income
−$266M
Free cash flow
−$217M
Operating margin
−519.8%
Ocular Therapeutix, Inc in 30 seconds · fiscal 2025
Are sales growing?
−18.5%
No. Sales fell 18.5% last year.
Does it make a profit?
−511.9%
No. It lost money last year.
Does profit turn into cash?
−417.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ocular Therapeutix, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 5, 2026
- Legal name
- OCULAR THERAPEUTIX, INC
- CIK
- 0001393434
Ocular Therapeutix, Inc · OCUL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Revenue growth | 150.1% | 18.3% | 13.5% | 9.0% | −18.5% |
| Gross margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Operating margin | −179.3% | −152.7% | −141.0% | −269.6% | −519.8% |
| Net income | −$6.6M | −$71.0M | −$80.7M | −$194M | −$266M |
| Net margin | −15.1% | −138.0% | −138.1% | −303.7% | −511.9% |
| Diluted EPS | −$0.98 | −$0.97 | −$1.02 | −$1.22 | −$1.42 |
| Cash | |||||
| Cash from operations | −$65.6M | −$59.6M | −$70.2M | −$135M | −$205M |
| Capital expenditure | $1.2M | $3.7M | $6.1M | $1.3M | $12.0M |
| Free cash flow | −$66.7M | −$63.3M | −$76.3M | −$136M | −$217M |
| FCF margin | −153.4% | −123.0% | −130.6% | −213.4% | −417.5% |
| Share count change | 35.2% | 0.6% | 3.6% | 84.9% | 18.3% |
| Debt and strength | |||||
| Cash and short-term investments | $164M | $102M | $196M | $392M | $737M |
| Shareholders' equity | $88.0M | $35.4M | $91.1M | $315M | $654M |
| Current ratio | 7.3x | 4.1x | 6.7x | 10.7x | 15.4x |
| Interest coverage | −11.7x | −11.2x | −7.3x | −12.7x | −22.8x |
| Returns and quality | |||||
| Return on equity | −8.0% | −115.2% | −127.6% | −95.2% | −54.9% |
| Return on tangible equity | −7.4% | −200.8% | −88.6% | −61.4% | −40.6% |
| Piotroski F-score | 3 | 3 | 3 | 3 | 3 |
| Altman Z'' | −5.2 | −12.4 | −5.5 | −0.8 | 3.5 |
Insiders bought, 12 months
$0.5M
1 insider
Insiders sold, 12 months
$3.3M
8 insiders
Of sales under plans
93%
$3.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ocular Therapeutix, Inc · OCUL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.50 a share, the company is worth $1.5B.
Source: SEC EDGAR XBRL filings (CIK 0001393434). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.